BDSX vs NEO
BDSX: Biodesix develops precision diagnostic tests powered by molecular and AI analysis to guide oncology treatment decisions for clinicians, payers, and biopharmaceutical companies. NEO: NeoGenomics is a clinical laboratory leader providing specialized cancer-focused genetic and molecular testing services for diagnostics and pharmaceutical research.
Side-by-side fundamentals
| Metric | BDSX | NEO | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $22.22 | $13.14 | |
| Market cap as of 2026-08-03 | $225M | $1.7B | |
| PEG as of 2026-08-03 | n/a | 1.27 | |
| Net margin as of 2026-08-03 | -33.3% | -13.3% | NEO higher |
| Gross margin as of 2026-08-03 | +82.1% | +43.1% | BDSX higher |
| Operating margin as of 2026-08-03 | -25.9% | -14.3% | NEO higher |
| ROE as of 2026-08-03 | -375.1% | -11.8% | NEO higher |
| ROA as of 2026-08-03 | -35.6% | -7.2% | NEO higher |
| Debt / equity as of 2026-08-03 | 5.09 | 0.41 | NEO lower |
| Revenue growth (YoY) as of 2026-08-03 | +29.1% | +10.9% | BDSX higher |
| Revenue CAGR (3y) SEC XBRL | +32.3% | n/a | |
| Beta as of 2026-08-03 | 0.58 | 1.78 | |
| 1-year return as of 2026-07-27 close | +149.1% | +108.9% | BDSX higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.